- Nachrichtendetail
-
28.06.2024 13:52:13 - dpa-AFX: Roche: Vabysmo Gets CHMP Recommendation For Third Indication
SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) said the European Medicines
Agency's Committee for Medicinal Products for Human Use has adopted a positive
opinion for the extension of the Vabysmo marketing authorisation to include the
treatment of visual impairment due to macular edema secondary to retinal vein
occlusion. The company expects a final decision from the European Commission in
the near future.
The CHMP decision is based on full 72-week data from the Phase III BALATON and
COMINO studies evaluating Vabysmo in more than 1,200 people with macular edema
due to branch and central RVO.
For More Such Health News, visit rttnews.com.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Agency's Committee for Medicinal Products for Human Use has adopted a positive
opinion for the extension of the Vabysmo marketing authorisation to include the
treatment of visual impairment due to macular edema secondary to retinal vein
occlusion. The company expects a final decision from the European Commission in
the near future.
The CHMP decision is based on full 72-week data from the Phase III BALATON and
COMINO studies evaluating Vabysmo in more than 1,200 people with macular edema
due to branch and central RVO.
For More Such Health News, visit rttnews.com.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
ROCHE HLDG AG GEN. | 855167 | Hamburg | 0,000 | 30.06.24 23:27:54 | ±0,000 | ±0,00% | 0,000 | 0,000 | 0,000 | 245,550 |
